Retacrit 4000unit Inj, 1ml

Manufacturer PFIZER U.S. Active Ingredient Epoetin Alfa-epbx(e POE e tin AL fa) Pronunciation E-POE-e-tin AL-fa EP-B-X
WARNING: This drug may raise the chance of heart attack, stroke, heart failure, blood clots, and death. Talk with the doctor.People with some types of cancer have died sooner when using this drug. This drug also raised the chance of tumor growth and the tumor happening again in these people. Talk with the doctor.Your doctor will need to watch your blood cell counts and follow you closely to change the dose to match your body's needs. Talk with your doctor.If you will be having surgery, talk with your doctor. You may need to take another drug to keep you from getting blood clots while you get this drug. @ COMMON USES: It is used to treat anemia.It is used to help lower the need for blood transfusions for certain surgeries.It may be given to you for other reasons. Talk with the doctor.
đŸˇī¸
Drug Class
Erythropoiesis-stimulating agent (ESA)
đŸ§Ŧ
Pharmacologic Class
Recombinant human erythropoietin
🤰
Pregnancy Category
Category C
✅
FDA Approved
May 2018
âš–ī¸
DEA Schedule
Not Controlled

Overview

â„šī¸

What is this medicine?

Retacrit is a medicine that helps your body make more red blood cells. It is used to treat anemia (low red blood cell count) caused by chronic kidney disease, chemotherapy for certain cancers, or in some HIV patients. It works like a natural substance in your body called erythropoietin.
📋

How to Use This Medicine

Proper Use of This Medication

To use this medication correctly, follow your doctor's instructions and read all the information provided. This medication is administered via injection into the fatty tissue under the skin or into a vein by a healthcare professional.

Self-Administration

If you will be giving yourself injections, your doctor or nurse will provide guidance on the proper technique. It is essential to follow their instructions carefully.

Precautions

Before using this medication, make sure to:

Not shake the container
Not use the medication if it has been shaken
Wash your hands before and after handling the medication
Check the solution for cloudiness, leakage, or particles, and do not use it if you notice any of these issues
Verify that the solution has not changed color
Avoid injecting into skin that is irritated, tender, bruised, red, scaly, hard, scarred, or has stretch marks

Disposal

After use, dispose of needles and other sharp objects in a designated needle/sharp disposal box. Do not reuse needles or other items. When the box is full, follow local regulations for proper disposal. If you have any questions, consult your doctor or pharmacist.

Storage and Disposal

For all products, follow the storage instructions provided. If you miss a dose, contact your doctor to determine the best course of action.
💡

Lifestyle & Tips

  • Maintain adequate iron intake, often requiring iron supplements as prescribed by your doctor.
  • Monitor your blood pressure regularly as instructed by your healthcare provider.
  • Report any new or worsening symptoms promptly to your doctor.
  • Do not shake the vial; shaking can damage the medicine.

Dosing & Administration

đŸ‘¨â€âš•ī¸

Adult Dosing

Standard Dose: Highly variable based on indication and patient response. Examples: CKD: Initial 50-100 units/kg IV or SC 3 times/week. Chemotherapy-induced anemia: Initial 150 units/kg SC 3 times/week or 40,000 units SC weekly.
Dose Range: 50 - 60000 mg

Condition-Specific Dosing:

Chronic Kidney Disease (CKD) Anemia: Initial 50-100 units/kg IV or SC 3 times/week. Titrate to maintain hemoglobin within target range (e.g., 10-11 g/dL).
Chemotherapy-Induced Anemia: Initial 150 units/kg SC 3 times/week or 40,000 units SC weekly. Titrate to maintain hemoglobin within target range (e.g., 10-11 g/dL).
Zidovudine-Treated HIV-Infected Patients: Initial 100 units/kg IV or SC 3 times/week. Titrate based on response.
Reduction of Allogeneic RBC Transfusions in Surgery: 300 units/kg/day SC for 10 days (5 days pre-op, day of surgery, 4 days post-op) or 600 units/kg SC once weekly (3 weeks pre-op, day of surgery).
đŸ‘ļ

Pediatric Dosing

Neonatal: Not established
Infant: Not established
Child: Chronic Kidney Disease (CKD) Anemia: Initial 50 units/kg IV or SC 3 times/week. Titrate to maintain hemoglobin within target range (e.g., 10-11 g/dL).
Adolescent: Chronic Kidney Disease (CKD) Anemia: Initial 50 units/kg IV or SC 3 times/week. Titrate to maintain hemoglobin within target range (e.g., 10-11 g/dL).
âš•ī¸

Dose Adjustments

Renal Impairment:

Mild: Used in CKD; dose adjusted based on hemoglobin response, not degree of impairment.
Moderate: Used in CKD; dose adjusted based on hemoglobin response, not degree of impairment.
Severe: Used in CKD; dose adjusted based on hemoglobin response, not degree of impairment.
Dialysis: Dosing for CKD patients on dialysis is similar to non-dialysis CKD patients, adjusted based on hemoglobin response. IV route often preferred for dialysis patients.

Hepatic Impairment:

Mild: No specific dose adjustment recommended.
Moderate: No specific dose adjustment recommended.
Severe: No specific dose adjustment recommended.

Pharmacology

đŸ”Ŧ

Mechanism of Action

Epoetin alfa-epbx is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. It interacts with the erythropoietin receptor on progenitor cells in the bone marrow to stimulate red blood cell production and differentiation.
📊

Pharmacokinetics

Absorption:

Bioavailability: 30-40% (subcutaneous)
Tmax: 5-24 hours (subcutaneous)
FoodEffect: Not applicable

Distribution:

Vd: Approximately 4-10 L
ProteinBinding: Not extensively protein bound
CnssPenetration: Limited

Elimination:

HalfLife: IV: 4-13 hours (CKD patients); SC: 13-45 hours
Clearance: Not readily quantifiable due to complex catabolism
ExcretionRoute: Primarily catabolism; minimal renal excretion of intact drug
Unchanged: <5%
âąī¸

Pharmacodynamics

OnsetOfAction: Hemoglobin levels begin to rise in 2-6 weeks.
PeakEffect: Peak hemoglobin response typically seen after several weeks of therapy.
DurationOfAction: Effects on erythropoiesis persist for several days after discontinuation due to the lifespan of red blood cells.

Safety & Warnings

âš ī¸

BLACK BOX WARNING

Increased risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor progression or recurrence. ESAs increase the risk of serious cardiovascular events and stroke when administered to target hemoglobin levels >11 g/dL. In cancer patients, ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies.
âš ī¸

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek immediate medical attention:

Signs of an allergic reaction: rash, hives, itching, red, swollen, blistered, or peeling skin (with or without fever), wheezing, tightness in the chest or throat, trouble breathing, swallowing, or talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat.
Signs of high blood pressure: severe headache, dizziness, fainting, or changes in vision.
Signs of high blood sugar: confusion, drowsiness, excessive thirst or hunger, frequent urination, flushing, rapid breathing, or fruity-smelling breath.
Signs of low potassium levels: muscle pain or weakness, muscle cramps, or an irregular heartbeat.
Rapid heartbeat.
Shortness of breath, significant weight gain, or swelling in the arms or legs.
Weakness on one side of the body, difficulty speaking or thinking, balance problems, drooping on one side of the face, or blurred vision.
Confusion.
Cool or pale arm or leg.
Difficulty walking.
Dizziness or fainting.
Excessive sweating.
Seizures.
Extreme fatigue or weakness.
Pale skin.
Depression.

Blood Clots and Severe Skin Reactions

If you experience any of the following symptoms, seek medical help immediately:

Signs of a blood clot: chest pain or pressure, coughing up blood, shortness of breath, swelling, warmth, numbness, color changes, or pain in a leg or arm, or difficulty speaking or swallowing.
Severe skin reaction (Stevens-Johnson syndrome/toxic epidermal necrolysis): red, swollen, blistered, or peeling skin (with or without fever), red or irritated eyes, or sores in the mouth, throat, nose, or eyes. This condition can cause severe health problems and may be life-threatening.

Other Possible Side Effects

Like all medications, this drug can cause side effects. While many people may not experience any side effects or only minor ones, it's essential to discuss any concerns with your doctor. If you experience any of the following side effects or any other symptoms that bother you or persist, contact your doctor:

Irritation at the injection site.
Fever or chills.
Headache.
Upset stomach or vomiting.
Cough.
Bone, joint, or muscle pain.
Muscle spasms.
Mouth irritation or mouth sores.
Weight loss.
Sleep disturbances.
* Common cold symptoms.

Reporting Side Effects

This list is not exhaustive, and you may experience other side effects. If you have questions or concerns, contact your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Chest pain, shortness of breath, or sudden weakness/numbness on one side of the body (signs of heart attack or stroke)
  • Sudden severe headache, confusion, or vision changes (signs of stroke or severe hypertension)
  • Pain, swelling, warmth, or redness in an arm or leg (signs of a blood clot)
  • Signs of an allergic reaction (rash, itching, hives, swelling of the face/lips/tongue/throat, severe dizziness, trouble breathing)
  • Unusual tiredness, dizziness, or pale skin (signs of worsening anemia or other issues)
📋

Before Using This Medicine

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following conditions before starting this medication:

Any allergies you have, including allergies to this drug, its components, or other substances, and describe the symptoms you experienced.
If you have high blood pressure.
If you are currently experiencing active bleeding.
If you have low levels of vitamins or minerals.
If you have a condition called Pure Red Cell Aplasia (PRCA), a type of anemia.

Additionally, if you are using a multi-dose container, tell your doctor:

If you are pregnant or think you might be pregnant. This medication is not recommended during pregnancy.
If you are breastfeeding. You should not breastfeed while taking this medication and for 2 weeks after your last dose.
If the patient is a premature baby or newborn. This form of the medication should not be given to premature babies or newborns.

This list is not exhaustive, and it is crucial to discuss all your medications (prescription, over-the-counter, natural products, and vitamins) and health issues with your doctor and pharmacist. They will help determine if it is safe to take this medication with your other drugs and health conditions. Never start, stop, or change the dose of any medication without consulting your doctor first.
âš ī¸

Precautions & Cautions

Important Information About Your Medication

It is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are taking this medication.

Monitoring Your Health

You will need to have your blood pressure checked regularly, as directed by your doctor, because this medication can cause high blood pressure. Additionally, your doctor will instruct you on when to have blood work done to monitor your health.

Special Considerations

If you have phenylketonuria (PKU), consult with your doctor before taking this medication, as some products contain phenylalanine.

Safe Use of Your Medication

Do not exceed the dosage prescribed by your doctor, as taking more than the recommended amount can increase the risk of severe side effects. If you accidentally take more than the prescribed dose, contact your doctor immediately.

Understanding the Effects of Your Medication

This medication can increase the production of red blood cells in your blood. Be aware that misuse or abuse of this type of medication can lead to serious health issues, including stroke, heart attack, and blood clots. If you have any questions or concerns, discuss them with your doctor.

Multi-Dose Container Precautions

This medication contains benzyl alcohol. If possible, avoid using products with benzyl alcohol in newborns or infants, as serious side effects can occur in these children, especially when combined with other medications containing benzyl alcohol. If you have questions, consult with your doctor.

Single-Dose Container Precautions

If you are pregnant, planning to become pregnant, or are breastfeeding, inform your doctor. You and your doctor will need to discuss the potential benefits and risks of this medication to both you and your baby.
🆘

Overdose Information

Overdose Symptoms:

  • Polycythemia (excessively high red blood cell count), which can lead to increased blood viscosity and risk of thrombotic events (blood clots), stroke, or heart attack.
  • Exacerbation of side effects like hypertension.

What to Do:

Management is supportive. If severe polycythemia occurs, phlebotomy (removal of blood) may be considered to reduce blood viscosity. Call 1-800-222-1222 (Poison Control) or seek immediate medical attention.

Drug Interactions

Monitoring

đŸ”Ŧ

Baseline Monitoring

Hemoglobin (Hb) and Hematocrit (Hct)

Rationale: To establish baseline anemia severity and guide initial dosing.

Timing: Prior to initiation of therapy.

Iron Status (Serum Ferritin, Transferrin Saturation (TSAT))

Rationale: Adequate iron stores are essential for optimal response to ESAs. Iron deficiency can lead to resistance.

Timing: Prior to and during therapy.

Blood Pressure

Rationale: Hypertension is a common side effect and can be exacerbated by ESA therapy.

Timing: Prior to initiation and regularly during therapy.

📊

Routine Monitoring

Hemoglobin (Hb)

Frequency: Weekly until stable, then every 2-4 weeks.

Target: Individualized, generally 10-11 g/dL. Avoid exceeding 11 g/dL.

Action Threshold: If Hb rises rapidly (>1 g/dL in 2 weeks) or exceeds target, reduce dose. If Hb does not increase or falls, investigate for iron deficiency or other causes of resistance.

Blood Pressure

Frequency: Regularly (e.g., weekly or bi-weekly initially, then monthly).

Target: Individualized, within patient's normal range.

Action Threshold: If significant increase, manage hypertension aggressively; consider dose reduction or temporary interruption of ESA.

Iron Status (Ferritin, TSAT)

Frequency: Periodically (e.g., every 1-3 months) or as needed.

Target: Ferritin >100 ng/mL, TSAT >20%.

Action Threshold: If iron stores are low, initiate or increase iron supplementation.

đŸ‘ī¸

Symptom Monitoring

  • Symptoms of anemia (fatigue, pallor, shortness of breath)
  • Symptoms of hypertension (headache, dizziness, blurred vision)
  • Symptoms of thrombotic events (chest pain, shortness of breath, sudden weakness or numbness on one side of the body, vision changes, pain/swelling in a limb)
  • Signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing)

Special Patient Groups

🤰

Pregnancy

Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown adverse effects, but there are no adequate and well-controlled studies in pregnant women.

Trimester-Specific Risks:

First Trimester: Potential for adverse developmental effects observed in animal studies.
Second Trimester: Potential for adverse developmental effects observed in animal studies.
Third Trimester: Potential for adverse developmental effects observed in animal studies.
🤱

Lactation

Considered compatible with breastfeeding (L2). Epoetin alfa is a large protein and is poorly excreted into milk. It is also inactivated in the infant's gastrointestinal tract. No adverse effects have been reported in breastfed infants.

Infant Risk: Low
đŸ‘ļ

Pediatric Use

Dosing is established for pediatric patients with CKD-associated anemia. Safety and efficacy for other indications (e.g., chemotherapy-induced anemia) have not been established in pediatric patients.

👴

Geriatric Use

No specific dose adjustment is required based on age alone. However, older patients may have an increased risk of cardiovascular events and should be monitored closely for hypertension and thrombotic complications.

Clinical Information

💎

Clinical Pearls

  • Iron supplementation is almost always required for optimal response to epoetin alfa-epbx, as iron deficiency is a common cause of resistance.
  • Do not shake the vial or syringe; shaking can denature the glycoprotein, rendering it inactive.
  • Target hemoglobin levels should be individualized and generally kept at the lowest level sufficient to avoid transfusions, typically not exceeding 11 g/dL, due to the increased risk of serious adverse cardiovascular events and stroke.
  • Monitor blood pressure closely, as hypertension is a common and potentially serious side effect.
  • Educate patients on the signs and symptoms of thrombotic events (e.g., DVT, PE, stroke, MI) and to seek immediate medical attention if they occur.
  • Retacrit is a biosimilar to Epogen/Procrit, meaning it is highly similar to and has no clinically meaningful differences from the reference product.
🔄

Alternative Therapies

  • Other Erythropoiesis-Stimulating Agents (ESAs) such as darbepoetin alfa (Aranesp) or methoxy polyethylene glycol-epoetin beta (Mircera)
  • Blood transfusions (for acute, severe anemia or when ESAs are contraindicated/ineffective)
  • Iron supplementation (oral or intravenous)
  • Treatment of underlying cause of anemia (e.g., nutritional deficiencies, bleeding, inflammatory conditions)
💰

Cost & Coverage

Average Cost: Varies widely, typically $50-$200+ per 4000 unit vial
Insurance Coverage: Tier 3 or 4, often requires prior authorization and/or step therapy.
📚

General Drug Facts

If your symptoms or health issues persist or worsen, it's essential to contact your doctor promptly. To ensure safe use, never share your medication with others or take someone else's medication. This medication is accompanied by a Medication Guide, which provides crucial information. Please read this guide carefully and review it again whenever you receive a refill. If you have any questions or concerns about this medication, don't hesitate to consult your doctor, pharmacist, or other healthcare provider. In the event of a suspected overdose, immediately call your local poison control center or seek emergency medical attention. Be prepared to provide details about the overdose, including the medication taken, the amount, and the time it occurred.